Completed PHASE1 INTERVENTIONAL 1-arm NCT02447601

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions Type 2 Diabetes Mellitus

Interventions PEX168 Simvastatin

Updated 6 times since 2017 Last updated: Jan 21, 2017 Started: Mar 30, 2015 Primary completion: May 14, 2015 Completion: Aug 11, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Type 2 Diabetes Mellitus and is currently completed. Jiangsu Hansoh Pharmaceutical Co., Ltd. leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Data source: Jiangsu Hansoh Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China